Physician profile
Geidy Rivers
NPI 1760839617
$3,516.48
in general payments reported to CMS, 2019-2025
17 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $236 · 2023: $1,037 · 2024: $1,211 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,280.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $1,089.12 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $495.98 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $357.72 | 2023-2024 | Farxiga |
| Teva Pharmaceuticals USA, INC. | $284.56 | 2022-2024 | Austedo Xr, Austedo |
| Lilly USA, LLC | $243.64 | 2023-2024 | Mounjaro |
| Otsuka America Pharmaceutical, INC. | $237.15 | 2022-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.32 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $158.16 | 2023 | Quviviq |
| Amgen INC. | $133.88 | 2024 | Otezla |
| Lundbeck LLC | $71.81 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $68.24 | 2022-2024 | Ingrezza |
| Alkermes, INC. | $61.02 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $60.74 | 2022-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $27.23 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.99 | 2023 | Xifaxan |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $23.70 | 2023 | Affirm Prone Biopsy System, Thinprep 2000 Processor, Aptima |
| Exact Sciences Corporation | $15.22 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geidy Rivers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.